MEN1 and acute myeloid leukemia: Small molecule inhibitors of the Menin‐KMT2A interaction (i.e. Revumenib) (Fig. 4A) have recently been developed that have shown promise in preclinical studies of AML driven by both KMT2A‐oncofusions and NPM1C mutations.